Share via:
Scientists at Melbourne’s Peter Doherty Institute for Infection and Immunity are working on a Crispr-based treatment — delivered as a nasal spray or injection — that could stop influenza infections by targeting the virus’s RNA and disrupting its ability to replicate inside human cells.
The approach uses the Cas13 enzyme, a lesser-known cousin of the DNA-cutting Cas9, which can be engineered to seek out conserved regions of influenza’s genetic code that are found in…
We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
Scientists at Melbourne’s Peter Doherty Institute for Infection and Immunity are working on a Crispr-based treatment — delivered as a nasal spray or injection — that could stop influenza infections by targeting the virus’s RNA and disrupting its ability to replicate inside human cells.
The approach uses the Cas13 enzyme, a lesser-known cousin of the DNA-cutting Cas9, which can be engineered to seek out conserved regions of influenza’s genetic code that are found in…
We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi
